Compare MasterCard Inc (MA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Organon & Co. Common Stock — how do they compare? MasterCard Inc trades at $606.33 (market cap $529.81B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: MasterCard Inc is far larger — about 146.4× Organon & Co. Common Stock's market cap, and MasterCard Inc is more actively traded (3,710,695 versus 2,892,999). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and Organon & Co. Common Stock for 0 Days on average.
| MA | OGN | |
|---|---|---|
Market Cap | $529.81B | $3.62B |
Volume | 3,710,695 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $604.80 | $13.81 |
52-Week Low | $471.55 | $5.70 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $542.84B | $11.04B |
Dividend Yield | 0.58% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $604.80, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining impressive profit margins above 45%. Recent earnings beats and institutional buying activity support the positive outlook, while the company continues expanding digital payment infrastructure globally.
Mastercard presents a compelling growth opportunity with 80% analyst buy ratings and a $668.67 consensus price target. Key risks include payment industry disruption from stablecoins and AI-driven competitors. The stock's premium valuation (P/E 33.27) requires sustained execution, but strong cash flow generation and strategic positioning support long-term upside potential.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
